LIXTE BIOTECHNOLOGY HOLDINGS, INC.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
NMAD$3.57-0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONSOLIDATED FINANCIAL STATEMENTS
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
(INCLUDING REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM)
Years Ended December 31, 2025 and 2024
| Page Number | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID NO. 572) | F-2 |
|---|---|
| Consolidated Balance Sheets - December 31, 2025 and 2024 | F-4 |
| Consolidated Statements of Operations - Years Ended December 31, 2025 and 2024 | F-5 |
| Consolidated Statements of Stockholders’ Equity - Years Ended December 31, 2025 and 2024 | F-6 |
| Consolidated Statements of Cash Flows - Years Ended December 31, 2025 and 2024 | F-7 |
| Notes to Consolidated Financial Statements - Years Ended December 31, 2025 and 2024 | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.